See the DrugPatentWatch profile for ozempic

Ozempic, also known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes. According to the drug's prescribing information, Ozempic can influence appetite in several ways [1]:

1. Delayed gastric emptying: Ozempic slows down the rate at which the stomach empties after eating, which can lead to a feeling of fullness and reduced appetite [1].

2. Central appetite regulation: GLP-1 receptors are present in several areas of the brain that regulate appetite and food intake. Activation of these receptors by Ozempic can result in reduced hunger and appetite, leading to decreased food consumption [1][2].

3. Weight loss: As a result of reduced appetite and calorie intake, Ozempic has been shown to cause weight loss in some patients. In clinical trials, patients taking Ozempic experienced an average weight loss of 4.5-6.2 kg (9.9-13.7 lbs) over a 26-56 week period, depending on the dosage [1].

It is important to note that individual responses to Ozempic may vary, and not all patients will experience the same effects on appetite and weight loss. Patients should consult their healthcare provider for personalized advice regarding the use of Ozempic and its potential impact on appetite [1].

Sources:
[1] Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use. Prescribing Information. 2021. <https://www.novo-pi.com/ozempic.pdf>
[2] Drugs.com. Ozempic. <https://www.drugs.com/ozempic.html>
[3] DrugPatentWatch.com. Ozempic (semaglutide) - Patent Expiration & Drug Sales Data. <https://www.drugpatentwatch.com/drugs/ozempic>